7th February - Mirena: The Next Chapter

Learning outcomes: Understand Mirena’s background - supporting Women across three licensed indications. Understand the new 8 year license extension in contraception and symptom-led HMB and the data to support it Be able to apply the licence extension, and understand how this will impact your practice and shape the Women’s Health landscape

Event overview:

Learning outcomes: Understand Mirena’s background - supporting Women across three licensed indications. Understand the new 8 year license extension in contraception and symptom-led HMB and the data to support it Be able to apply the licence extension, and understand how this will impact your practice and shape the Women’s Health landscape

Bayer is delighted to announce the licence extension to Mirena^® in contraception which now is 8 years and the symptom-led extension in idiopathic Heavy Menstrual Bleeding (HMB) for up to 8 years should symptoms not return after 5 years of use.¹

Speakers:

Dr Diana Mansour

Consultant in Community Gynaecology and Reproductive Healthcare

Dr Paula Briggs

Consultant in Sexual and Reproductive Health

1. Mirena SmPC 2024

Endometrial protection indication has not changed from 4 years.

All education events